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ABSTRACT
Background. AJCC staging of pancreatic cancer (PAC) is
used to determine prognosis, yet survival within each stage
shows wide variation and remains unpredictable. We
hypothesizedthattumorgrademightberesponsibleforsome
of this variation and that the addition of grade to current
AJCC staging would provide improved prognostication.
Methods. The Surveillance, Epidemiology, and End
Results (SEER) database (1991–2005) was used to identify
8082 patients with resected PAC. The impact of grade on
overall and stage-speciﬁc survival was assessed using Cox
regression analysis. Variables in the model were age, sex,
tumor size, lymph node status, and tumor grade.
Results. For each AJCC stage, survival was signiﬁcantly
worse for high-grade versus low-grade tumors. On multi-
variate analysis, high tumor grade was an independent
predictor of survival for the entire cohort (hazard ratio
[HR] 1.40, 95% conﬁdence interval [95% CI] 1.31–1.48) as
well as for stage I (HR 1.28, 95% CI 1.07–1.54), stage IIA
(HR 1.43, 95% CI 1.26–1.61), stage IIB (HR 1.38, 95% CI
1.27–1.50), stage III (HR 1.28, 95% CI 1.02–1.59), and
stage IV (HR 1.58, 95% CI 1.21–2.05) patients. The
addition of grade to staging results in a statistically sig-
niﬁcant survival discrimination between all stages.
Conclusions. Tumor grade is an important prognostic
variable of survival in PAC. We propose a novel staging
system incorporating grade into current AJCC staging for
pancreas cancer. The improved prognostication is more
reﬂective of tumor biology and may impact therapy deci-
sions and stratiﬁcation of future clinical trials.
The American Joint Commission on Cancer (AJCC)
tumor node metastasis (TNM) staging system is the ‘‘lan-
guage of cancer’’ by which physicians communicate about
the disease process.
1 Staging ensures an objective, repro-
ducible classiﬁcation of the extent of disease and is our
most important determinant of treatment recommendations.
For research purposes, clinical trials depend on staging for
appropriate patient stratiﬁcation upon which accurate
measurement of the treatment effect under study can be
performed. Perhaps most importantly to the patient, staging
is our best tool to provide prognostic information in our
effort to manage patient expectations in the context of a
suggested treatment plan.
Current staging for pancreatic cancer is based on the 6th
edition of the AJCC Cancer Staging Manual, published in
2002 (Table 1).
2 This update has been validated for pan-
creatic cancer using the National Cancer Database (NCDB)
and shown to have good survival discrimination between
stages.
3 However, because survival within a particular
stage is highly variable, the Memorial Sloan Kettering
Cancer Center (MSKCC) developed a nomogram to better
predict the likelihood of disease-speciﬁc survival after
initial resection for pancreatic carcinoma.
4 This nomogram
incorporates additional factors into the predictive model
not included in traditional TNM staging, one of which is
the degree of differentiation or grade of the tumor. Pre-
dictions by the nomogram discriminated better than AJCC
stage, suggesting that incorporation of additional variables
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Several other multivariate analyses have shown that
tumor grade is an important prognostic indicator after
resection of pancreatic cancer.
6–11 Grade is a measure of the
degree of differentiation of the tumor. Differentiation refers
to the morphologic and functional resemblance between a
tumor cell and a normal cell of the same tissue. Malignant
neoplasms range from well differentiated (low grade) to
undifferentiated (high grade); in general, the more undif-
ferentiated the tumor, the more aggressive the malignant
biology.
12 For pancreatic adenocarcinomas, histologic
grade is based on the extent of glandular differentiation. If
[95% of the tumor is composed of glands then it is clas-
siﬁed as being well differentiated, 50%–95% is moderately
differentiated, and\50% is poorly differentiated.
2
The aim of this study was to use a population-based
database providing signiﬁcant power to assess the impact of
tumor grade on prognosis after resection for pancreatic
cancer. We hypothesized that some of the variability in
survival within the same AJCC stage might be the result of
differences in tumor grade. Our goal was to assess the
signiﬁcance of tumor grade as a predictive factor indepen-
dent of known adverse predictors of survival. Furthermore,
we sought to develop a novel staging system that would
incorporate grade into the existing TMN system in hopes of
providing improved staging that is more reﬂective of the
underlying tumor biology and associated survival.
METHODS
SEER Database
The National Cancer Institute’s Surveillance, Epidemi-
ology, and End Results (SEER) tumor registry database was
used for this study. SEER contains more than 3 million
cases from 17 geographic sites, covering approximately
26% of the U.S. population. The database was designed to
reﬂect the overall characteristics of the U.S. population and
is regarded as a model population-based tumor registry.
Quality control is an important component of the SEER
program; the current standard for accuracy of the data in the
registry is an error rate of less than 5%.
13 SEER Program
registries routinely collect data on patient demographics
(e.g., age, sex), primary tumor characteristics (e.g., size,
extent, grade), nodal staging (number of nodes examined,
number of positive nodes), surgery performed (pancreati-
coduodenectomy vs distal pancreatectomy), vital status, and
survival. Although information on radiation therapy is
recorded, no information on chemotherapy is reported. The
November 2007 update was used for this study, providing
TABLE 1 American Joint
Committee on Cancer (AJCC)
6th edition TNM staging system
for pancreatic cancer
T stage (primary tumor)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor limited to pancreas and B2c m
T2 Tumor limited to pancreas and[2c m
T3 Tumor extends beyond pancreas
T4 Tumor extends beyond pancreas and involves the celiac axis or superior mesenteric artery
(unresectable)
N stage (regional lymph nodes)
NX Regional nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
M stage (distant sites)
MX Distant metastasis cannot be assessed
M1 Distant metastasis
Stage grouping
Stage 0 Tis N0 M0 Localized
Stage IA T1 N0 M0 Localized
Stage IB T2 N0 M0 Localized
Stage IIA T3 N0 M0 Locally invasive
Stage IIB T1–3 N1 M0 Locally invasive
Stage III T4 Any N M0 Unresectable
Stage IV Any T Any N M1 Distant metastasis
Grade in Pancreatic Cancer 2313information from 1973 to 2005.
14 As a population-based
study with no patient identiﬁers involved, our study was
exempt from institutional research board review.
Case Selection
The study period was from 1991 to 2005. The ICD-10
histology codes 8000, 8010, 8020, 8021, 8140, 8141, and
8500 were used to identify all patients with a diagnosis of
adenocarcinoma of the pancreas. Patients who did not
undergo cancer-directed surgery were excluded from the
analysis. Also excluded were patients with no histological
conﬁrmation of the diagnosis and cases identiﬁed from
autopsy reports only. Although no speciﬁc ﬁeld for AJCC
stage in pancreatic cancer is provided in the SEER data-
base, the information to accurately stage patients is present
in other data ﬁelds. Using extent of disease (EOD) data
ﬁelds, we were able to determine stage according to the 6th
edition of the AJCC Staging Manual, as our group and
others have done so previously.
15,16 Complete TNM data
were available for 7627 out of 8082 patients (94.4%) using
the EOD codes. In the SEER database, tumor grade is
coded as 1 (well differentiated), 2 (moderately differenti-
ated), 3 (poorly differentiated), or 4 (undifferentiated).
Tumor grade was recorded for 7086 out of 8082 patients
(88%).
Statistical Analysis
Kaplan–Meier curves and log-rank tests were used to
identify differences in overall survival, deﬁned as duration
of survival after initial resection of pancreatic carcinoma.
Predictors of survival after surgical resection for the entire
cohort were identiﬁed by Cox regression analysis using
proportional hazards modeling. Variables included in the
model were age, sex, tumor size, lymph node status, and
tumor grade. Only patients with complete data were
included in the multivariate analysis. Thus, 5935 of 8082
patients were eligible for inclusion in the multivariate
analysis. A separate multivariate analysis was performed to
identify predictors of survival for stages I, IIA, IIB, III, and
IV individually. Stages IA and IB were combined together
to ensure adequate numbers for analysis. For stages I, IIA,
and IIB variables in the model were age, sex, tumor size,
and tumor grade only. Lymph node status was not included
because by deﬁnition all patients in stages I and IIA are
node negative and patients in stage IIB are node positive.
In our study, grade was redeﬁned as a dichotomous, cate-
gorical variable: tumor grades 1 (well differentiated) and 2
(moderately differentiated) were combined into a ‘‘low-
grade’’ group and tumor grades 3 (poorly differentiated)
and 4 (undifferentiated) into a ‘‘high-grade’’ group. Cate-
gorical variables were compared between low-grade and
high-grade groups using chi-square analysis. Differences
between continuous variables were determined using t test.
Signiﬁcance levels were set at P\.05 and conﬁdence
intervals were 95%. All tests were two-tailed. Predictors of
high tumor grade were identiﬁed using logistic regression
analysis. Factors included in the model were sex, tumor
size, lymph node status, and presence of extrapancreatic
invasion. Patients with incomplete data were excluded
from regression analysis. All statistical analysis was per-
formed using SPSS 16.0 statistical software (SPSS Inc.,
Chicago IL).
RESULTS
Our study population consisted of 8082 patients who
underwent resection of pancreatic adenocarcinoma.
Demographic, tumor, and treatment characteristics of the
entire cohort as well as low-grade and high-grade groups
are detailed in Table 2. A total of 996 (12%) patients did
not have tumor grade recorded. Signiﬁcant differences
were seen between the high-grade and low-grade cohort
with regard to sex, tumor size, lymph node involvement,
number of positive nodes, AJCC stage, and reception of
radiation treatment.
For each AJCC stage classiﬁcation, survival was sig-
niﬁcantly worse with high-grade (3 or 4) versus low-grade
(1 or 2) tumors (Fig. 1). Multivariate analysis of the entire
cohort identiﬁed the following independent predictors of
adverse outcome: increasing age, male sex, tumor size
[2 cm, lymph node positivity, and high tumor grade.
Importantly, the hazard ratio (HR) associated with high
tumor grade (HR = 1.4) was of a similar magnitude and
signiﬁcance when compared with tumor size (HR = 1.37)
and node status (HR = 1.38). When each stage was ana-
lyzed separately, high tumor grade remained an
independent predictor of survival across all stages
(Table 3). Interestingly, in the stage IV patients who
underwent a resection, grade was the only independent
prognostic variable (HR = 1.58).
Predictors of high tumor grade were tumor size[2c m
(odds ratio [OR] 1.39, 95% conﬁdence interval [95% CI]
1.18–1.65, P\.001), positive lymph nodes (OR 1.24, 95%
CI 1.08–1.42, P = .002), and peripancreatic invasion (OR
1.20, 95% CI 1.03–1.41, P = .02). Female sex was a
protective factor (OR .85, 95% CI .74–.97, P = .013).
Tumor grade (G) was incorporated into AJCC (TNM)
staging system to generate a novel TNMG staging system
for 6862 out of 8082 patients (84.9%). This TNMG staging
differs from the AJCC staging by advancing a patient to the
next higher stage level in the presence of high tumor grade
(Table 4). For instance a high-grade stage IIA tumor in the
TNM staging system would now be a stage IIB tumor in
2314 N. Wasif et al.the novel TNMG system. By restaging patients in this
manner, the impact of grade on survival can be realized, as
demonstrated by a 2-month improvement in median sur-
vival of stage IIA patients simply by advancing patients
with high-grade tumors and associated worse survival into
stage IIB. Excellent discrimination in overall survival
between stages is also seen in this novel TNMG staging
classiﬁcation and appears to be durable throughout all time
points as the curves remain separate through 5 years
(Fig. 2).
DISCUSSION
The aim of this study was to use a population-based
tumor registry to assess the impact of tumor grade on
prognosis after surgical resection for pancreatic cancer. We
believe that the variability in survival within each AJCC
stage may be attributed to factors not currently incorpo-
rated into the staging system, one of which is tumor grade.
Our data show that within each AJCC stage, high tumor
grade is an independent and signiﬁcant predictor of adverse
TABLE 2 Demographic,
tumor and treatment
characteristics
Percentages may not add up to
100 due to rounding
AJCC American Joint
Committee on Cancer
a Low grade included grades 1
and 2; high grade included
grades 3 and 4. Excluded from
these 2 columns were 996
patients for whom data were
unavailable
Demographics All patients
(n = 8082)
Low-grade tumor
a
(n = 4491)
High-grade tumor
a
(n = 2595)
P value
Sex (%) .009
Male 50.4 49.0 52.3
Age (y) NS
Mean ± SD 65.2 ± 11.0 65.2 ± 10.8 65.3 ± 10.9
Median 66.0 66.3 66.5
Race (%) NS
White 83.1 82.9 84.2
Black 9.9 9.9 9.2
Other 6.8 7.3 6.6
Tumor location (%) NS
Head 85.6 85.7 85.4
Body 5.1 5.2 4.9
Tail 9.4 9.1 9.7
Type of surgery (%) NS
Whipple procedure 82.4 82.2 82.7
Distal pancreatectomy 9.3 9.4 9.2
Total pancreatectomy 8.3 8.4 8.0
Tumor size (cm) \.001
Mean ± SD 3.5 ± 1.9 3.4 ± 1.8 3.7 ± 2.1
Median 3.1 3.0 3.4
Lymph node status (%) \.001
Positive 60.3 57.9 64.6
AJCC state (%) \.001
IA 4.3 5.2 2.7
IB 8.1 8.7 7
IIA 24.6 25.7 22.7
IIB 49.5 48.6 51
III 6.8 6.5 7.4
IV 6.7 5.2 9.1
Number of nodes examined NS
Mean ± SD 9.8 ± 8.0 9.8 ± 8.0 9.8 ± 8.0
Median 8.0 8.0 8.0
Number of positive nodes .006
Mean ± SD 2.9 ± 2.6 2.9 ± 2.5 3.1 ± 2.7
Median 2.1 2.0 2.6
Radiation (%) .001
Yes 42.7 44.2 40.2
Grade in Pancreatic Cancer 2315outcome. When patients are restaged with grade incorpo-
rated into a novel TNMG staging system, excellent
discrimination in survival between stages is seen.
The largest series on surgical resection for pancreatic
cancer in the literature includes 1423 patients who under-
went pancreaticoduodenectomies at the Johns Hopkins
Medical Institutions.
8 Among other variables, the authors
report histologic grade as an independent predictor of
survival on multivariate analysis, with a hazard ratio of 1.6.
Other single-institution studies have conﬁrmed this on both
univariate and multivariate analysis with a hazard ratio that
varies between 1.14 and 2.56.
9–11 Our population-based
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a. Stage I
Low grade, n = 605, median 25 mos.
High grade, n = 245, median 17 mos.
p = 0.001
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b. Stage IIA
Low grade, n = 1122, median 18 mos.
High grade, n = 577, median 13 mos.
p = 0.000
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c. Stage IIB
Low grade, n = 2103, median 15 mos.
High grade, n = 1295, median 11 mos.
p = 0.000
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d. Stage III
Low grade, n = 281, median 13 mos.
High grade, n = 188, median 9 mos.
p = 0.016
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e. Stage IV
Low grade, n = 226, median 8 mos.
High grade, n = 232, median 5 mos.
p = 0.000
FIG. 1 Kaplan-Meier survival curves stratiﬁed by grade for patients with stage I (a), stage IIA (b), stage IIB (c), stage III (d), and stage IV (e)
disease
2316 N. Wasif et al.study reports a hazard ratio of 1.40 for high tumor grade,
which falls well within the range reported in the literature.
Largely in concert with published studies, we found
tumor size [2 cm, lymph node positivity, age, and male
sex as adverse prognostic factors for the entire cohort.
Tumor size and lymph node involvement are well-known
prognostic indicators for pancreatic cancer and, along with
distant metastases, form the trifecta of the current TNM-
based AJCC staging for pancreatic cancer. Many studies
have shown that patients with a tumor larger than 2 cm or
lymph node involvement have a signiﬁcantly lower median
and 5-year survival.
6–11,17–21 Other studies show that
patients who are elderly have a worse outcome than
younger patients after surgical resection of pancreatic
cancer.
22,23 Similarly, we also show that males have poorer
survival than females, which may be related to the presence
of lower-grade tumors in females as demonstrated by our
data.
4,5
Especially pertinent to the context of our study are
clinical trials for adjuvant treatment of pancreatic cancer.
In the CONKO-001 trial of adjuvant gemcitabine versus
observation after resection of pancreatic cancer, the median
overall survival was 22.8 months in the gemcitabine group
and 20.2 months in the observation group (P = .005).
24
Similarly in the ESPAC-1 trial, adjuvant chemotherapy
with 5-ﬂuorouracil/leucovorin had a statistically signiﬁcant
beneﬁt over observation with respect to median survival
(20.1 vs 15.5 months, P = .009).
25 Lastly, the RTOG 97–
04 trial randomized patients to chemoradiotherapy using
5FU versus chemoradiotherapy with gemcitabine. The
results demonstrated a 3.7-month difference in median
survival in favor of the chemoradiotherapy/gemcitabine
TABLE 3 Cox regression analyses
Patient group Hazard ratio (95% CI) P value
Entire cohort (n 5 5935)
Age (y)
\55
a 1.00
56–65 1.10 (1.01–1.21) .037
66–75 1.26 (1.16–1.37) \.001
[75 1.48 (1.35–1.64) \.001
Sex
Female
a 1.00
Male 1.07 (1.00–1.13) .035
Node status
Negative
a 1.00
Positive 1.38 (1.30–1.47) \.001
Tumor size (cm)
\2
a 1.00
[2 1.37 (1.27–1.48) \.001
Tumor grade
Low
a 1.00
High 1.40 (1.31–1.48) \.001
Stage I (n 5 845)
Age (y)
\55
a 1.00
56–65 1.21 (.92–1.58) .18
66–75 1.50 (1.17–1.91) .001
[75 1.72 (1.31–2.26) \.001
Tumor size (cm)
\2
a 1.00
[2 1.33 (1.11–1.60) .002
Tumor grade
Low
a 1.00
High 1.28 (1.07–1.54) .007
Stage IIA (n 5 1501)
Tumor size (cm)
\2
a 1.00
[2 1.27 (1.10–1.47) .001
Tumor grade
Low
a 1.00
High 1.43 (1.26–1.61) \.001
Stage IIB (n 5 3140)
Age (y)
\55
a 1.00
56–65 1.04 (.92–1.17) .543
66–75 1.23 (1.10–1.38) \.001
[75 1.54 (1.34–1.76) \.001
Tumor size (cm)
\2
a 1.00
[2 1.37 (1.23–1.54) \.001
Tumor grade
Low
a 1.00
High 1.38 (1.27–1.50) \.001
TABLE 3 continued
Patient group Hazard ratio (95% CI) P value
Stage III (n 5 384)
Age (y)
\55
a 1.00
56–65 1.19 (.86–1.64) .29
66–75 1.37 (1.00–1.86) .047
[75 1.81 (1.28–2.57) .001
Tumor grade
Low
a 1.00
High 1.28 (1.02–1.59) .032
Stage IV (n 5 270)
Tumor grade
Low
a 1.00
High 1.58 (1.21–2.05) .001
n = patients with all variables available for regression analysis
a Referent
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26 In none of these trials were patients stratiﬁed by
grade. Given the magnitude of difference in median sur-
vival in these adjuvant trials and the potential impact of
grade on survival, it is feasible that stratifying upon grade
could alter the median survival difference and possibly the
signiﬁcance of these trial results. We have shown that
stratifying AJCC stage IIB resected tumors (node positive)
by grade demonstrates a 4-month improvement in median
survival for node-positive, low-grade tumors compared
with node-positive, high-grade tumors, which is compara-
ble to the difference in median survival seen in the trial
results quoted previously. Some may argue that randomi-
zation would automatically adjust for this factor; however,
given the degree to which most trials in pancreatic cancer
are underpowered, the risk for bias resulting from inaccu-
rate stratiﬁcation becomes much greater with such an
inﬂuential factor such as grade. This study shows that high
tumor grade (HR 1.40) has a larger impact on survival than
both node positivity (HR 1.38) and tumor size[2c m( H R
1.37), both of which are part of the current AJCC staging
system and are used to risk stratify patients routinely.
Our data make a strong case for inclusion of tumor grade
into current staging for pancreatic cancer; therefore, we
proposed a novel TNMG staging system. With the addition
of grade to the current AJCC staging system, we are better
able to tease out the ‘‘best case scenario’’ patients in stage
IA (low-grade tumors,\2 cm, node negative and localized
to the pancreas) and show an improvement in median
survival of 3 months compared with stage IA in TNM
staging (\2 cm, node negative and localized). We can also
identify the ‘‘bad actors’’ in stage IIA (high-grade tumors,
node negative, and locally invasive) and move them to
stage IIB in TNMG staging; again an improvement in
median survival of 2 months compared with stage IIA in
TNM staging. Furthermore, dividing stage IV patients into
stage IVA (low grade with median survival 8 months) and
stage IVB (high grade with median survival 5 months)
provides better risk stratiﬁcation in the very patient popu-
lation most likely to enroll in future clinical trials to
evaluate potential new therapies. Moreover, in support of
our contention that discrimination in survival is
improved with TNMG staging, the overall ‘‘spread’’ in
median survival for TNMG staging is 25 months (range
5–30 months), which compares with 21 months with TNM
staging (range 6–27 months).
TABLE 4 Restaging according
to TNMG classiﬁcation TNM 
Stage 
Median survival 
(months) 
Tumor 
Grade  
TNMG 
Stage  
Median survival 
(months) 
Low  IA  30  IA  27 
High 
Low   IB  21  IB 21 
High 
Low   IIA  18  IIA 16 
High 
Low   IIB  14  IIB 14 
High 
Low   III  11  III 11 
High 
IV  6 Low     IVA  8 
   High  IVB  5 
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FIG. 2 Kaplan-Meier survival curves based on TNMG classiﬁcation
showing excellent discrimination between stages
2318 N. Wasif et al.Importantly, we demonstrate that not only does addition
of tumor grade makes sense given its signiﬁcant and
independent impact on survival, but it can be added to the
existing TNM staging system in a relatively simple man-
ner. In other words, the novel TNMG staging system
proposed does not create a more complex staging system
but rather builds upon the existing AJCC staging system
with improved reﬂection of the underlying biology and
associated impact on survival. This is not a trivial point as
more complex staging systems such as the previously
mentioned nomograms have not been widely adopted in
spite of improved prognostication.
Tumor grade is already part of staging for prostate
cancer, sarcomas, and certain bone tumors. For a prog-
nostic factor to be included in the staging system, it must
explain some of the heterogeneity associated with the
expected course and outcome of a disease.
1 Our analysis
shows that tumor grade in pancreatic cancer meets this
criterion. Pathology studies of pancreatic cancer have
examined a scoring system based on grade, similar to
Gleason score for prostate cancer, and have shown good
predictive ability as well as reproducibility.
27 Similarly
Eltoum et al. devised a cytologic grading system for biopsy
specimens obtained by endoscopic ultrasound-guided ﬁne-
needle aspiration to predict survival in patients with pan-
creatic adenocarcinoma.
28
The use of population-based data has several inherent
limitations. Even though the database is checked regularly
for discrepancy and reportedly has 95% accuracy, the
possibility of coding errors remains. Furthermore, we
cannot account for variability among SEER regions in
pathology protocols used to assess tumor grade, as well as
interobserver variability among pathologists. As mentioned
previously, no information on chemotherapy is provided in
the database so we were unable to assess the impact of
adjuvant therapy. Additionally, margin status is not recor-
ded in SEER. Nevertheless, the use of a population
database enables us to study a large contemporary sample
of patients and make signiﬁcant statistical conclusions
relevant to the general population, which is not possible in
single-institution studies.
In this study we use the SEER cancer registry to show
that tumor grade is a signiﬁcant and independent prog-
nostic factor for survival after resection of pancreatic
adenocarcinoma. In fact, high tumor grade has a greater
impact on survival in pancreatic cancer than known poor
prognostic factors such as lymph node positivity and tumor
size, which form the basis of our current staging system.
We believe inclusion of tumor grade into AJCC staging for
pancreatic cancer would enhance the current system and
provide better survival prognostication reﬂective of the
aggressive biology associated with high-grade tumors.
These ﬁndings may have implications for adjuvant therapy
decision making as well as risk stratiﬁcation of patients
entering future clinical trials.
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